Hui Shao

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2021 · 319 citations

Medicine, Oncology, Pharmacology +10

Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma

Henny J. M. Beckers, Florent Aptel, Carroll A.B. Webers et al. · Ophthalmology Glaucoma · 2021 · 138 citations · Full text

Medicine, Ophthalmology, Surgery +16

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng et al. · Liver Cancer · 2021 · 129 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +12

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Michael J. Pishvaian, M.S. Lee, Baek‐Yeol Ryoo et al. · Annals of Oncology · 2018 · 74 citations · Full text

Medicine, Oncology, Pharmacology +14

The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.

Ping-Yu Lee, Hui Shao, Liang Xu et al. · PubMed · 1988 · 68 citations

Medicine, Ophthalmology, Pharmacology +11